BR112022017700A2 - Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol - Google Patents

Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol

Info

Publication number
BR112022017700A2
BR112022017700A2 BR112022017700A BR112022017700A BR112022017700A2 BR 112022017700 A2 BR112022017700 A2 BR 112022017700A2 BR 112022017700 A BR112022017700 A BR 112022017700A BR 112022017700 A BR112022017700 A BR 112022017700A BR 112022017700 A2 BR112022017700 A2 BR 112022017700A2
Authority
BR
Brazil
Prior art keywords
tapentadol
dosage form
phosphoric acid
form providing
extended release
Prior art date
Application number
BR112022017700A
Other languages
English (en)
Portuguese (pt)
Inventor
Bertram Ulrike
Reinhold Ulrich
Grosse Christian
Hartmann Carmen
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74701506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022017700(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20160419.6A external-priority patent/EP3875077B1/en
Priority claimed from EP20160420.4A external-priority patent/EP3875079A1/en
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR112022017700A2 publication Critical patent/BR112022017700A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022017700A 2020-03-02 2021-03-01 Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol BR112022017700A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20160419.6A EP3875077B1 (en) 2020-03-02 2020-03-02 Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP20160420.4A EP3875079A1 (en) 2020-03-02 2020-03-02 Dosage form providing prolonged release of tapentadol phosphoric acid salt
PCT/EP2021/055025 WO2021175773A1 (en) 2020-03-02 2021-03-01 Dosage form providing prolonged release of tapentadol phosphoric acid salt

Publications (1)

Publication Number Publication Date
BR112022017700A2 true BR112022017700A2 (pt) 2023-01-17

Family

ID=74701506

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017700A BR112022017700A2 (pt) 2020-03-02 2021-03-01 Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol

Country Status (7)

Country Link
EP (1) EP4003318A1 (es)
BR (1) BR112022017700A2 (es)
CO (1) CO2022012567A2 (es)
DE (1) DE202021003994U1 (es)
MX (1) MX2022010780A (es)
PE (1) PE20230105A1 (es)
WO (1) WO2021175773A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003318A1 (en) 2020-03-02 2022-06-01 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
AU2007309408A1 (en) 2006-10-27 2008-05-02 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
PL2352494T3 (pl) 2008-10-30 2020-03-31 Grünenthal GmbH Nowe i silne postaci dawkowania tapentadolu
PT3650439T (pt) 2010-07-23 2021-03-03 Gruenenthal Gmbh Sais ou cocristais de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP3027214A1 (en) 2013-08-02 2016-06-08 ratiopharm GmbH Composition comprising tapentadol in a dissolved form
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
ES2966219T3 (es) 2016-04-19 2024-04-19 Ratiopharm Gmbh Fosfato de tapentadol amorfo
ES2963929T3 (es) 2017-05-29 2024-04-03 Gruenenthal Gmbh Forma farmacéutica oral multipartículas que proporciona liberación prolongada de tapentadol
EP4003318A1 (en) 2020-03-02 2022-06-01 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt

Also Published As

Publication number Publication date
CO2022012567A2 (es) 2022-09-09
MX2022010780A (es) 2022-09-26
PE20230105A1 (es) 2023-01-25
DE202021003994U1 (de) 2022-04-12
WO2021175773A1 (en) 2021-09-10
EP4003318A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
BR112018003898A2 (pt) material auxiliar para aplicação no tecido de cólon
BR112015004192A2 (pt) sulfamoíl-arilamidas e o seu uso como medicamentos para o tratamento da hepatite b
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112013020537A2 (pt) suspensão aquosa e pó de liberação prolongada que compreendem metilfenidato
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015002421A2 (pt) composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112016022499A2 (pt) Produtos terapêuticos combinatórios supramoleculares
GT201400215A (es) Compuestos de indol e indazol que activan la ampk
BR112022017700A2 (pt) Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112015012197A2 (pt) terapia de combinação
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112015022092A8 (pt) derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo
HRP20201703T1 (hr) Liječenje kokcidioze intramuskularnim triazinskim pripravcima
BR112014029708A8 (pt) Composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
BR112015011213A2 (pt) Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112012003907A2 (pt) composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês
CL2013003057A1 (es) Composicion farmaceutica de aerosol en forma de solución acuosa para nebulización que comprende iloprost, que proporciona una dosis unica eficaz aerolizada para inhalacion de bolo en un periodo de menos de 2 minutos; kit farmacéutio, util en el tratamiento de hipertension arterial pulmonar.
BR112015007360A8 (pt) Composição farmacêutica, e, método para a preparação de uma droga de combinação